MAGALDRATE 400MG + SIMETHICONE 20MG ORAL SUSPENSION

Magaldrate 400Mg + Simethicone 20Mg Oral Suspension is a liquid drug in which Pharamaceutical Magnelt Pharmaceutical Magaldrate and Simethicone are the active ingredients. The right particle dispersion, vehicle formula, suspension product stability, physical stability and viscosity must be monitored during the product development process of these combinations to maintain a uniform suspension. Since these formulation contain dispersed solid material with Simethicone, proper wetting, mixing and homogenizing processes would be required when manufacturing in the product development process. This Oral suspension can be included in the PCD Pharma Franchise product list in a pharmaceutical company with various liquid formulation that has a comon quality and packaging specifications.

Composition Type and Formulation Recommendations

The formulation presently specified contains Magnelt Pharmaceutical Magaldrate 400Mg + Simethicone 20Mg in the final formulation of an oral suspension. Due to the active ingredients present, Magnelt pharmaceutical Magnelt pharmaceutical Magnelt is used as a dispersed pharmaceutical ingredient, while Simethicone can be administered via the dispersing process as indicated. This formulation may contain appropriate suspending and wetting agents, viscosity builders, flavorings, sweeteners, preservatives and other pharmaceutical excipients as required.

Each excipient should be selected for functional suitability and compatibility with the active ingredients.

Potential preformulation studies may be performed to assess particle size distribution and bulk density of the dispersed powders, sedimentation rate, viscosity, pH and product compatibility. The Vehicle may need to be designed to have adequate physical stability and to allow the dense material to be distributed evenly after adequate shaking. The formulation is thus optimized for stable rheology and dispersion characteristics.

Importance of Particle Dispersion in the formulation

Uniform Magnagled is one aspect that can significantly influence the dispersing of the particles in formulation Magaldrate 400Mg + Simethicone 20Mg Oral Suspension. Particle size and density can influence the rate of sedimentation, the viscosity and the redispersability of the dense material. Hence particle wetting of Magnagled is sometimes done before incorporating it into the vehicle, followed by the addition of a dispersing agent where indicated.

Simethicone is added through a similar process as the vehicle preparation, with such process and processing conditions being optimized based on the choice of vehicle.

Conversely, the use of dispersons, wetting agents and viscosity modifiying agents to hydrate or disperse the excipients may be incorporated into the formulation at different stages before blending Magnagled and Simethicone. Homogenization can be performed to promote better mixing where appropriate, with a focus on avoiding excess aeration.

Manufacturing Process and In-Process controls

Formulation Preparation. Appropriate amounts of Magnagent, Simethicone and other ingredients are weighed by the manufacturer against the set specifications. The vehicle is then prepared in suitable manufacturing vessel with controlled processing conditions.

Dispersons, viscosity modifiers or other aqueous components are then prepared before combining with the active ingredients during formulation.

Magnalet can be added slowly, using controlled agitation to aid wettability and dispersion. Simethicone is then added, again with controlled processing for homogeneous dispersion. Proper hydration of various excipients may be carried out before combining with the active ingredient mixture. Homogenization can be carried out to optimize dispersion.

Flushing, filling and flushing can be used to transfer the mixture, with minimal loss of losses.

In-Process Testing and Finished Product Evaluation

The final mixture may then be tested for appearance, pH, viscosity and sedimentation rate amongst other parameters to verify bulk quality. Microbial testing and container compatibility studies can be carried out while phase I stability data may be collected according to the use case, with appropriate monitoring for the physical parameters.

Sample Testing and Optimization

This formulation would be subjected to appropriate physical testing in order to verify the sedimentation rate and redispersability in order to optimize the formulation. Appropriate tests such as appearance, color, smell, pH, viscosity, fill volume etc. would also be used to optimize the product. Suitable analytical procedures can be developed for the identification and quantitative analysis of various ingredients in the final formulation with steps to minimize contamination and Microbology testing.

Final Formulation and Packaging Recommendations

MAGALDRATE 400Mg + SIMETHICONE 20Mg ORAL SUSPENSION would be attractive to the market, with its specific product composition optimized for good stability and disperability. The formulation can be used for quality control in order to verify the sedimentation rate and redispersability during evaluation of physical product parameters. Common quality parameters should include appearance, color, smell, pH, viscosity, sedimentation rate and redispersability, amongst others.

Suitable analytical parameters can be developed for the various ingredients that can be used to verify the final formulation.

The final liquid form should be filled in pharmaceutical-grade bottles with media compatible with the final formulation, which allow adequate shaking and dispense. The final use of the product would be considered before finalizing the specification details with good quality margins to classify the speed of penetration.

# Product Development and Portfolio

This formulation would make the product suitable for inclusion into pharmaceutical company portfolio along with syrup, drops and dry suspension preparations. The formulation can be used for inclusion as an oral formulation for various indications for people, with standardized composition, packaging and documentation. For the PCD Pharma Franchise this product can be developed with accurate composition, dosage strength, pack size, manufacturer details and other specific user details, with packaging artwork matching the finalized formulation details and specifications.